Mesothelin-targeted cell therapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new type of cell therapy (CAR-T cells) that is designed to find and attack cancer cells showing a protein called mesothelin. It may be an option for people with advanced solid tumors who have exhausted standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have a solid tumor cancer (like mesothelioma, pancreatic, lung, ovarian, or breast) that has not responded to standard treatment or has returned.
- Your tumor must show a specific protein called mesothelin, which this treatment targets.
- You must be in generally good health, able to care for yourself, and have a life expectancy of at least 3 months.
- Your heart, liver, kidney, and blood counts must be within safe limits for this therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a therapy using your own immune cells (T cells) modified to target mesothelin (MSLN), a protein found on some cancer cells. It may help people with certain advanced solid tumors that have not responded to or can't tolerate standard treatments.
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
This trial tests a new treatment called KT032, a type of CAR-T cell therapy, for people with advanced solid tumors (like ovarian cancer, mesothelioma, or colon cancer) that have spread to the belly lining. The treatment is given as an injection and is designed to target a protein called mesothelin on cancer cells. The goal is to see if it's safe and if it can help shrink tumors.
This early-phase study tests a lab-made immune cell therapy (CAR T cells) that targets a protein called mesothelin (MSLN) in advanced or metastatic solid cancers. It may help your body better recognize and attack tumor cells, especially if standard first treatments did not work or are not available.
This study tests a new kind of immunotherapy called CAR T-cells that are designed to find and attack cancer cells with a protein called mesothelin on their surface. It may help people with mesothelioma or other solid tumors that have not improved with standard treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) that target a protein called MSLN on cancer cells, and also release a special antibody to block two other proteins (PD-1 and CTLA-4) that cancers use to hide from the immune system. It is for people with advanced solid tumors like non-small-cell lung cancer or mesothelioma who have not responded to standard treatments.
Hear when a new Mesothelin-positive Advanced Malignant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.